The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Inclusion Criteria: * Histologically confirmed advanced or metastatic gastric or gastroesophageal junction adenocarcinoma * ECOG PS 0-2 * At least one measurable or evaluable lesion in the first-line chemotherapy * The fist line treatment should be 5-FU based regimen (e.g. ECF/EOF/EOX/FOLFOX/XELOX/XP) , and patients should received 6 cycles (3-week regimen) or 12 cycles (2-week regimen) treatment with the efficacy of non-PD * The time from the last cycle treatment to the enrollment cannot exceed 6 weeks * Adequate hepatic, renal, heart, and hematologic functions (platelets ≥75×109/L, neutrophil ≥1.5×109/L, hemoglobin ≥80 g/L, serum creatinine ≤1.5mg/dl, total bilirubin ≤1.5mg/dl, and serum transaminase ≤2.5× the ULN) Exclusion Criteria: * Received 2 or more regimens for palliative chemotherapy * Pregnant or lactating women * Concurrent cancer, or history of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * Uncontrolled brain, or leptomeningeal involvement, complete intestinal obstruction * Clinically significant active bleeding, OB 2+ or higher * Patients with locally advanced gastric cancer who are scheduled to receive radiotherapy * Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or high risk/uncontrolled arrhythmia * Uncontrolled significant comorbid conditions